Barrow Robert 4

What Happened
Robert Barrow, CEO of Definium Therapeutics, received an award of 375,000 common shares (reported as an award/grant, Code A) on 2026-06-22 at an acquisition price of $0.00 (total reported cost $0). These shares represent the first tranche of performance share units (PSUs) granted effective March 12, 2025 and remain subject to vesting and achievement of specified clinical and regulatory milestones.

Key Details

• Transaction date: 2026-06-22; Form 4 filed 2026-06-22.
• Transaction type: Award/Grant (Code A); 375,000 shares; price $0.00 (award).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: The 375,000 shares are PSUs — each PSU is a contingent right to one common share, subject to continued employment through March 12, 2028 and satisfaction of clinical/regulatory milestones per the award agreement. This represents the first tranche of the PSU grant effective March 12, 2025.
• Timeliness: No late filing indicated in the provided information.

Context
Performance share units are compensation grants that only convert to actual shares if specified service and performance conditions are met; they are not the same as an open-market purchase or immediate cash proceeds. Because these PSUs are contingent and subject to vesting and milestone achievement, they do not necessarily reflect an immediate change in the CEO’s economic exposure or signal a near-term trading intent.